 CAMBRIDGE, Mass., March 15, 2022 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. NASDAQ:MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the Companys Phase 1 trial of upifitamab rilsodotin UpRi at the upcoming Society of Gynecologic Oncology Annual Meeting on Womens Cancer being held from March 18-21, 2022 in Phoenix, Arizona. 